화학요법 유발 빈혈 시장 규모, 점유율 및 성장 분석 : 치료법별, 암 유형별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Chemotherapy Induced Anemia Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.61 Billion in 2025 to USD 2.52 Billion by 2033, growing at a CAGR of 5.81% during the forecast period (2026-2033).

The global chemotherapy induced anemia market comprises various products and services aimed at preventing, diagnosing, and treating anemia associated with chemotherapy, including erythropoiesis-stimulating agents, iron supplements, and biosimilars. With a significant portion of chemotherapy patients experiencing hemoglobin levels below 10 g/dL, the need for effective interventions is critical, as it impacts patients' quality of life and increases healthcare costs. The market has transitioned from blood-cell growth factors to newer agents due to safety concerns, leading to innovation and diversification. Addressing iron deficiency with intravenous treatments not only reduces transfusion needs but also shortens hospital stays, presenting economic advantages for healthcare providers. Manufacturers are adapting by introducing biosimilar epoetins and combination kits, enhancing care quality and driving down costs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chemotherapy Induced Anemia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chemotherapy Induced Anemia Market Segments Analysis

Global chemotherapy induced anemia market is segmented by treatment, cancer type, distribution, end-user and region. Based on treatment, the market is segmented into Erythropoiesis-Stimulating Agents (ESAs), Blood Transfusion, Iron Supplements and HIF-PHI Drugs (Pipeline). Based on cancer type, the market is segmented into Solid Tumors and Hematologic Malignancies. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Oncology Centers and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chemotherapy Induced Anemia Market

The rising prevalence of cancer among various populations leads to a higher number of patients receiving chemotherapy, a treatment often associated with the development of anemia. This condition necessitates ongoing demand for effective therapies aimed at safely restoring hemoglobin levels and enhancing patient quality of life. As a result, healthcare providers and oncology centers increasingly prioritize approved anemia management solutions, contributing to the continuous growth of the market. Furthermore, advocacy organizations highlight the importance of addressing anemia to alleviate fatigue and promote adherence to chemotherapy treatments, further solidifying the upward trend of the chemotherapy-induced anemia market.

Restraints in the Global Chemotherapy Induced Anemia Market

The high cost of biologic erythropoietin products presents significant challenges for healthcare systems, especially in low- and middle-income areas where limited budgets restrict drug acquisition. Payers frequently implement strict reimbursement policies that emphasize cost-effectiveness, prompting healthcare providers to explore alternative, more affordable treatments or to delay necessary interventions. This financial strain not only hinders the uptake of premium therapies but also stunts overall market expansion, as manufacturers struggle to gain widespread acceptance in various healthcare settings. Additionally, hospitals often prioritize funding for other services, which can result in delayed investments in anemia management solutions and subsequently reduce market demand.

Market Trends of the Global Chemotherapy Induced Anemia Market

The Global Chemotherapy Induced Anemia market is witnessing a significant trend toward personalized therapy integration, emphasizing tailored anemia management based on individual patient characteristics such as genetics and chemotherapy regimens. This approach not only enhances treatment efficacy but also minimizes adverse events, leading to increased demand for advanced diagnostic tools that assess iron metabolism and erythropoietic response. As clinicians adopt precision oncology practices, there is a growing focus on developing companion diagnostics and customizable dosing formulations. This shift is broadening market potential by promoting adaptive dosing schedules and biomarker-guided treatments, ultimately aiming to improve patient outcomes and enhance overall therapeutic effectiveness worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Chemotherapy Induced Anemia Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Erythropoiesis-Stimulating Agents (ESAs)
• Blood Transfusion
• Iron Supplements
• HIF-PHI Drugs (Pipeline)

Global Chemotherapy Induced Anemia Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Solid Tumors
• Hematologic Malignancies

Global Chemotherapy Induced Anemia Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Chemotherapy Induced Anemia Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Oncology Centers
• Hospitals

Global Chemotherapy Induced Anemia Market Size & CAGR (2026-2033)

• North America (Treatment, Cancer Type, Distribution, End-User)
  • US
  • Canada
• Europe (Treatment, Cancer Type, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Cancer Type, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Cancer Type, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Cancer Type, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (Epogen, Aranesp)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Procrit/Eprex)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (NeoRecormon)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma (CSL Behring)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Roxadustat)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (Roxadustat)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (Daprodustat)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3SBio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Drugs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reliance Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations